renaissance capital, page-38

Write this down and we will judge French and his team based on these quoted time frames:

1.  "Our lead product candidate, TT-034,.....We expect to receive efficacy data in the fourth quarter of 2015. If the results of the trial are favorable, we anticipate commencing a Phase IIb/III trial in the second quarter of 2017."

2.  "We are also developing Hepbarna, which currently is in preclinical studies, for the treatment of the hepatitis B virus, or HBV. We plan to file an investigational new drug, or IND, application in the first quarter of 2017."

3.  "We plan to submit IND applications for our drug-resistant NSCLC product candidate in the third quarter of 2016..."

4.  "our HBV and AMD product candidates in the first and second quarters of 2017, respectively.."

5.  "In addition to TT-034 for HCV and Hepbarna for HBV, we are focusing on developing product candidates to treat AMD, OPMD and drug-resistant NSCLC. For selected product candidates, at the appropriate stage, we may collaborate with large pharmaceutical companies to further develop and, if approved, commercialize them to achieve broad product distribution."

We'll be watching, or not.